

## SUPPLEMENTAL MATERIAL

Lepore et al., <http://www.jem.org/cgi/content/full/jem.20140410/DC1>**Table S1.** Clinical characteristics of pediatric patients

Patient	Gender/age <i>yr</i>	Malignancy	Risk	Blast CD1 expression
<b>Pediatric AML</b>				
p-AML-01	M/15	AML	H	CD1b-CD1c
p-AML-02	M/15	sAML MD	H	CD1b-CD1c
p-AML-03	F/12	AML	H	CD1b-CD1c
p-AML-04	M/18	AML	L	CD1b-CD1c
p-AML-05	F/8	AML	L	Negative
p-AML-06	F/18	AML	H	Negative
p-AML-07	F/2	sAML MD	H	Negative
p-AML-08	F/1	AML	H	Negative
p-AML-09	F/7	AML	H	Negative
<b>Pediatric B-ALL</b>				
p-BALL-01	M/13	B-ALL	I	CD1c-CD1d
p-BALL-02	M/4	B-ALL	H	CD1b-CD1c
p-BALL-03	M/5	B-ALL	I	Negative
p-BALL-04	F/6	B-ALL	H	Negative
p-BALL-05	F/2	B-ALL	S	Negative
p-BALL-06	F/13	B-ALL	S	Negative
p-BALL-07	F/2	B-ALL	I	Negative
p-BALL-08	M/8	B-ALL	H	CD1b-CD1c
p-BALL-09	M/7	B-ALL	H	Negative
p-BALL-10	F/8	B-ALL	S	Negative
p-BALL-11	F/9	B-ALL	S	Negative
p-BALL-12	M/16	B-ALL	H	Negative
p-BALL-13	F/6	B-ALL	S	Negative
p-BALL-14	M/-	B-ALL	I	CD1b-CD1c
p-BALL-15	M/7	B-ALL	S	Negative
p-BALL-16	F/4	B-ALL	H	CD1c
p-BALL-17	F/4	B-ALL	I	Negative
p-BALL-18	F/3	B-ALL	I	Negative
p-BALL-19	M/3	B-ALL	S	Negative
p-BALL-20	F/-	B-ALL	n.e.	CD1a-CD1b
p-BALL-21	M/9	B-ALL	S	Negative
p-BALL-22	F/13	B-ALL	I	Negative
p-BALL-23	F/9	B-ALL	I	CD1b-CD1c
<b>Pediatric T-ALL</b>				
p-TALL-01	M/5	T-ALL	H	CD1a-CD1b
p-TALL-02	M/14	T-ALL	S	CD1a-CD1b-CD1d
p-TALL-03	M/7	T-ALL	H	CD1a-CD1b
p-TALL-04	M/7	T-ALL	S	CD1a-CD1b-CD1d
p-TALL-05	M/7	T-ALL	H	CD1a-CD1b-CD1c-CD1d
p-TALL-06	M/13	T-ALL	S	CD1a-CD1b-CD1d
p-TALL-07	F/8	T-ALL	H	Negative
p-TALL-08	F/7	T-ALL	H	Negative

sAML MD, secondary AML from myelodysplastic syndrome. Disease risk: H, high risk; S, standard risk; I, intermediate risk; L, low risk; n.e., not evaluated.

**Table S2.** Clinical characteristics of adult patients

Patient	Gender/age yr	Malignancy	Risk	Blast CD1 profile
<b>Adult AML</b>				
a-AML-01	M/39	sAML	A	Negative
a-AML-02	M/56	AML	A	CD1b-CD1c
a-AML-03	F/29	AML	A	CD1b-CD1c
a-AML-04	F/54	AML	F	CD1b-CD1c-CD1d
a-AML-05	F/64	sAML MD	A	CD1b-CD1c-CD1d
a-AML-06	F/38	AML	I	Negative
a-AML-07	F/59	AML	A	CD1b-CD1c-CD1d
a-AML-08	F/64	AML	I	CD1b-CD1c
a-AML-09	M/21	sAML	A	CD1b-CD1c
a-AML-10	F/28	sAML MD	A	CD1b-CD1c
a-AML-11	F/53	AML	A	Negative
a-AML-12	F/53	AML	A	CD1b-CD1c
a-AML-13	F/56	AML	A	CD1b-CD1c-CD1d
a-AML-14	M/74	AML	I	Negative
a-AML-15	M/64	AML	A	Negative
a-AML-16	M/77	AML	A	CD1b-CD1c
a-AML-17	F/62	AML	I	Negative
a-AML-18	M/45	AML	A	CD1b-CD1c
a-AML-19	F/59	AML	A	None
a-AML-20	M/60	sAML MD	A	CD1b-CD1c
a-AML-21	M/69	AML	F	CD1a
a-AML-22	F/58	sAML MD	A	Negative
a-AML-23	F/50	AML	F	CD1d
a-AML-24	M/52	AML	A	CD1d
a-AML-25	F/52	AML	A	Negative
a-AML-26	F/84	AML	A	CD1b
a-AML-27	F/70	AML	A	Negative
a-AML-28	F/39	AML	A	CD1b-CD1c-CD1d
a-AML-29	F/39	AML	A	CD1b-CD1c-CD1d
a-AML-30	M/57	AML	F	CD1b-CD1c
a-AML-31	M/42	AML	A	Negative
a-AML-32	F/67	AML	A	CD1b-CD1c
a-AML-33	F/61	sAML	A	Negative
<b>Adult B-ALL</b>				
a-BALL-01	M/61	B-ALL	VH	Negative
a-BALL-02	M/78	B-ALL	VH	CD1c
a-BALL-03	F/47	B-ALL	VH	CD1c
a-BALL-04	M/22	B-ALL	n.e.	Negative
a-BALL-05	M/42	B-ALL	VH	CD1c, CD1d
a-BALL-06	F/38	B-ALL	H	CD1c, CD1d
a-BALL-07	F/78	B-ALL	VH	CD1c

sAML MD, secondary AML from myelodysplastic syndrome. Disease risk for AML: A, adverse; I, intermediate; F, favorable. Disease risk for B-ALL: VH, very high risk; n.e., not evaluated.

**Table S3.** C16 and C17 mLPA MRM transitions

Compound	Transition	Cone voltage	Collisional energy	Dwell time
		V	eV	s
C16 mLPA	408.96 > 110.84 <sup>a</sup>	20	25	0.025
	408.96 > 376.97	20	35	0.025
C17 mLPA	423.06 > 110.89 <sup>a</sup>	20	25	0.025
	423.06 > 391.02	20	35	0.025

<sup>a</sup>Quantification ion.